Which has stronger valuation & earnings, NEPH or LFWD?

Nephros has higher earnings, but lower revenue than Lifeward. Lifeward is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nephros $19.12M 2.00 $1.19M $0.07 50.23 Lifeward $20.92M 0.93 -$19.91M -$19.66 N/A

Is NEPH or LFWD more profitable?

Nephros has a net margin of 4.06% compared to Lifeward's net margin of -123.66%. Nephros' return on equity of 7.66% beat Lifeward's return on equity. Company Net Margins Return on Equity Return on Assets Nephros 4.06% 7.66% 5.86% Lifeward -123.66% -243.14% -97.39%

Which has stronger earnings & valuation, TELA or LFWD?

Lifeward has lower revenue, but higher earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TELA Bio $80.81M 0.49 -$38.83M -$0.79 N/A Lifeward $20.92M 0.93 -$19.91M -$19.66 N/A

Is TELA or LFWD more profitable?

TELA Bio has a net margin of -49.30% compared to Lifeward's net margin of -123.66%. Lifeward's return on equity of -243.14% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets TELA Bio -49.30% -1,320.81% -55.83% Lifeward -123.66% -243.14% -97.39%

Which has preferable valuation and earnings, CTSO or LFWD?

Cytosorbents has higher revenue and earnings than Lifeward. Cytosorbents is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cytosorbents $37.06M 0.78 -$8.20M -$0.19 N/A Lifeward $20.92M 0.93 -$19.91M -$19.66 N/A

Is CTSO or LFWD more profitable?

Cytosorbents has a net margin of -31.85% compared to Lifeward's net margin of -123.66%. Cytosorbents' return on equity of -235.57% beat Lifeward's return on equity. Company Net Margins Return on Equity Return on Assets Cytosorbents -31.85% -235.57% -37.88% Lifeward -123.66% -243.14% -97.39%

Lifeward (LFWD) Competitors

$6.94 -0.23 (-3.14%)

As of 12:35 PM Eastern

Compare

LFWD vs. NEPH, TELA, MLSS, NMTC, and CTSO

Should you buy Lifeward stock or one of its competitors? MarketBeat compares Lifeward with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lifeward include Nephros (NEPH), TELA Bio (TELA), Milestone Scientific (MLSS), NeuroOne Medical Technologies (NMTC), and Cytosorbents (CTSO). These companies are all part of the "medical equipment" industry.

How does Lifeward compare to Nephros?

Nephros (NASDAQ:NEPH) and Lifeward (NASDAQ:LFWD) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Nephros has higher earnings, but lower revenue than Lifeward. Lifeward is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$19.12M	2.00	$1.19M	$0.07	50.23
Lifeward	$20.92M	0.93	-$19.91M	-$19.66	N/A

In the previous week, Lifeward had 12 more articles in the media than Nephros. MarketBeat recorded 13 mentions for Lifeward and 1 mentions for Nephros. Nephros' average media sentiment score of 1.33 beat Lifeward's score of 0.14 indicating that Nephros is being referred to more favorably in the media.

Company	Overall Sentiment
Nephros	Positive
Lifeward	Neutral

41.1% of Nephros shares are owned by institutional investors. Comparatively, 26.8% of Lifeward shares are owned by institutional investors. 6.7% of Nephros shares are owned by company insiders. Comparatively, 1.5% of Lifeward shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Nephros presently has a consensus target price of $6.00, indicating a potential upside of 70.65%. Lifeward has a consensus target price of $10.00, indicating a potential upside of 43.99%. Given Nephros' stronger consensus rating and higher possible upside, equities research analysts plainly believe Nephros is more favorable than Lifeward.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lifeward	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Nephros has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market. Comparatively, Lifeward has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market.

Nephros has a net margin of 4.06% compared to Lifeward's net margin of -123.66%. Nephros' return on equity of 7.66% beat Lifeward's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	4.06%	7.66%	5.86%
Lifeward	-123.66%	-243.14%	-97.39%

Summary

Nephros beats Lifeward on 13 of the 15 factors compared between the two stocks.

How does Lifeward compare to TELA Bio?

TELA Bio (NASDAQ:TELA) and Lifeward (NASDAQ:LFWD) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

TELA Bio has a net margin of -49.30% compared to Lifeward's net margin of -123.66%. Lifeward's return on equity of -243.14% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TELA Bio	-49.30%	-1,320.81%	-55.83%
Lifeward	-123.66%	-243.14%	-97.39%

TELA Bio currently has a consensus target price of $2.20, indicating a potential upside of 149.15%. Lifeward has a consensus target price of $10.00, indicating a potential upside of 43.99%. Given TELA Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe TELA Bio is more favorable than Lifeward.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Lifeward	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Lifeward had 13 more articles in the media than TELA Bio. MarketBeat recorded 13 mentions for Lifeward and 0 mentions for TELA Bio. TELA Bio's average media sentiment score of 0.94 beat Lifeward's score of 0.14 indicating that TELA Bio is being referred to more favorably in the media.

Company	Overall Sentiment
TELA Bio	Positive
Lifeward	Neutral

Lifeward has lower revenue, but higher earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TELA Bio	$80.81M	0.49	-$38.83M	-$0.79	N/A
Lifeward	$20.92M	0.93	-$19.91M	-$19.66	N/A

TELA Bio has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market. Comparatively, Lifeward has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market.

94.3% of TELA Bio shares are owned by institutional investors. Comparatively, 26.8% of Lifeward shares are owned by institutional investors. 4.7% of TELA Bio shares are owned by insiders. Comparatively, 1.5% of Lifeward shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

TELA Bio beats Lifeward on 11 of the 16 factors compared between the two stocks.

How does Lifeward compare to Milestone Scientific?

Milestone Scientific (NYSE:MLSS) and Lifeward (NASDAQ:LFWD) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

In the previous week, Lifeward had 13 more articles in the media than Milestone Scientific. MarketBeat recorded 13 mentions for Lifeward and 0 mentions for Milestone Scientific. Lifeward's average media sentiment score of 0.14 beat Milestone Scientific's score of 0.00 indicating that Lifeward is being referred to more favorably in the news media.

Company	Overall Sentiment
Milestone Scientific	Neutral
Lifeward	Neutral

Milestone Scientific has higher earnings, but lower revenue than Lifeward. Milestone Scientific is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Scientific	$8.90M	4.00	-$6.93M	-$0.05	N/A
Lifeward	$20.92M	0.93	-$19.91M	-$19.66	N/A

5.8% of Milestone Scientific shares are owned by institutional investors. Comparatively, 26.8% of Lifeward shares are owned by institutional investors. 12.5% of Milestone Scientific shares are owned by company insiders. Comparatively, 1.5% of Lifeward shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Milestone Scientific has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Lifeward has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market.

Milestone Scientific currently has a consensus price target of $1.00, indicating a potential upside of 147.52%. Lifeward has a consensus price target of $10.00, indicating a potential upside of 43.99%. Given Milestone Scientific's stronger consensus rating and higher probable upside, analysts clearly believe Milestone Scientific is more favorable than Lifeward.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Scientific	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Lifeward	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Milestone Scientific has a net margin of -52.01% compared to Lifeward's net margin of -123.66%. Milestone Scientific's return on equity of -60.26% beat Lifeward's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Scientific	-52.01%	-60.26%	-40.23%
Lifeward	-123.66%	-243.14%	-97.39%

Summary

Milestone Scientific beats Lifeward on 10 of the 15 factors compared between the two stocks.

How does Lifeward compare to NeuroOne Medical Technologies?

NeuroOne Medical Technologies (NASDAQ:NMTC) and Lifeward (NASDAQ:LFWD) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

NeuroOne Medical Technologies has higher earnings, but lower revenue than Lifeward. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroOne Medical Technologies	$9.72M	3.03	-$3.61M	-$0.85	N/A
Lifeward	$20.92M	0.93	-$19.91M	-$19.66	N/A

NeuroOne Medical Technologies currently has a consensus target price of $11.67, indicating a potential upside of 241.53%. Lifeward has a consensus target price of $10.00, indicating a potential upside of 43.99%. Given NeuroOne Medical Technologies' stronger consensus rating and higher probable upside, analysts clearly believe NeuroOne Medical Technologies is more favorable than Lifeward.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Lifeward	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

NeuroOne Medical Technologies has a net margin of -68.35% compared to Lifeward's net margin of -123.66%. NeuroOne Medical Technologies' return on equity of -98.33% beat Lifeward's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroOne Medical Technologies	-68.35%	-98.33%	-69.85%
Lifeward	-123.66%	-243.14%	-97.39%

In the previous week, Lifeward had 13 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 13 mentions for Lifeward and 0 mentions for NeuroOne Medical Technologies. NeuroOne Medical Technologies' average media sentiment score of 0.93 beat Lifeward's score of 0.14 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
NeuroOne Medical Technologies	Positive
Lifeward	Neutral

16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 26.8% of Lifeward shares are owned by institutional investors. 11.8% of NeuroOne Medical Technologies shares are owned by insiders. Comparatively, 1.5% of Lifeward shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

NeuroOne Medical Technologies has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Lifeward has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market.

Summary

NeuroOne Medical Technologies beats Lifeward on 12 of the 16 factors compared between the two stocks.

How does Lifeward compare to Cytosorbents?

Cytosorbents (NASDAQ:CTSO) and Lifeward (NASDAQ:LFWD) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

Cytosorbents has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market. Comparatively, Lifeward has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market.

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 26.8% of Lifeward shares are owned by institutional investors. 7.3% of Cytosorbents shares are owned by company insiders. Comparatively, 1.5% of Lifeward shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cytosorbents has a net margin of -31.85% compared to Lifeward's net margin of -123.66%. Cytosorbents' return on equity of -235.57% beat Lifeward's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-31.85%	-235.57%	-37.88%
Lifeward	-123.66%	-243.14%	-97.39%

In the previous week, Lifeward had 12 more articles in the media than Cytosorbents. MarketBeat recorded 13 mentions for Lifeward and 1 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 0.94 beat Lifeward's score of 0.14 indicating that Cytosorbents is being referred to more favorably in the media.

Company	Overall Sentiment
Cytosorbents	Positive
Lifeward	Neutral

Cytosorbents currently has a consensus price target of $5.38, indicating a potential upside of 1,068.48%. Lifeward has a consensus price target of $10.00, indicating a potential upside of 43.99%. Given Cytosorbents' stronger consensus rating and higher probable upside, analysts clearly believe Cytosorbents is more favorable than Lifeward.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lifeward	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Cytosorbents has higher revenue and earnings than Lifeward. Cytosorbents is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.78	-$8.20M	-$0.19	N/A
Lifeward	$20.92M	0.93	-$19.91M	-$19.66	N/A

Summary

Cytosorbents beats Lifeward on 12 of the 15 factors compared between the two stocks.

Get Lifeward News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LFWD vs. The Competition

Export

Metric	Lifeward	INTERNET SOFTWARE Industry	Computer Sector	NASDAQ Exchange
Market Cap	$19.54M	$17.17B	$39.25B	$12.17B
Dividend Yield	N/A	2.93%	3.06%	5.32%
P/E Ratio	-0.35	62.36	80.67	23.90
Price / Sales	0.93	26.61	613.06	90.24
Price / Cash	N/A	76.33	51.18	55.53
Price / Book	1.26	6.27	9.93	6.48
Net Income	-$19.91M	$386.39M	$1.06B	$337.00M
7 Day Performance	-12.53%	-4.35%	-0.84%	-2.19%
1 Month Performance	-0.79%	1.66%	6.92%	1.37%
1 Year Performance	-51.37%	-7.05%	162.93%	30.14%

Lifeward Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LFWD Lifeward	1.7734 of 5 stars	$6.95 -3.1%	$10.00 +44.0%	-51.4%	$19.54M	$20.92M	N/A	60	Analyst Downgrade Analyst Revision
NEPH Nephros	2.8203 of 5 stars	$3.58 +0.1%	$6.00 +67.5%	+8.1%	$38.89M	$19.12M	51.18	30	Positive News
TELA TELA Bio	3.2621 of 5 stars	$0.86 +5.7%	$2.20 +155.8%	-53.1%	$38.59M	$80.81M	N/A	120
MLSS Milestone Scientific	N/A	$0.39 +3.5%	$1.00 +159.7%	-52.3%	$33.91M	$8.90M	N/A	30	Gap Down
NMTC NeuroOne Medical Technologies	2.4264 of 5 stars	$3.90 +0.7%	$11.67 +199.2%	-3.7%	$33.32M	$9.72M	N/A	20	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LFWD) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lifeward (LFWD) Competitors

LFWD vs. NEPH, TELA, MLSS, NMTC, and CTSO

How does Lifeward compare to Nephros?

Summary

How does Lifeward compare to TELA Bio?

Summary

How does Lifeward compare to Milestone Scientific?

Summary

How does Lifeward compare to NeuroOne Medical Technologies?

Summary

How does Lifeward compare to Cytosorbents?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFWD vs. The Competition

Lifeward Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lifeward (LFWD) Competitors

LFWD vs. NEPH, TELA, MLSS, NMTC, and CTSO

How does Lifeward compare to Nephros?

Which has stronger valuation & earnings, NEPH or LFWD?

Does the media refer more to NEPH or LFWD?

Do institutionals & insiders believe in NEPH or LFWD?

Do analysts recommend NEPH or LFWD?

Which has more risk and volatility, NEPH or LFWD?

Is NEPH or LFWD more profitable?

Summary

How does Lifeward compare to TELA Bio?

Is TELA or LFWD more profitable?

Do analysts prefer TELA or LFWD?

Does the media refer more to TELA or LFWD?

Which has stronger earnings & valuation, TELA or LFWD?

Which has more volatility & risk, TELA or LFWD?

Do insiders & institutionals believe in TELA or LFWD?

Summary

How does Lifeward compare to Milestone Scientific?

Does the media prefer MLSS or LFWD?

Which has higher valuation and earnings, MLSS or LFWD?

Do insiders and institutionals believe in MLSS or LFWD?

Which has more risk & volatility, MLSS or LFWD?

Do analysts recommend MLSS or LFWD?

Is MLSS or LFWD more profitable?

Summary

How does Lifeward compare to NeuroOne Medical Technologies?

Which has higher earnings and valuation, NMTC or LFWD?

Do analysts rate NMTC or LFWD?

Is NMTC or LFWD more profitable?

Does the media refer more to NMTC or LFWD?

Do insiders & institutionals believe in NMTC or LFWD?

Which has more risk & volatility, NMTC or LFWD?

Summary

How does Lifeward compare to Cytosorbents?

Which has more risk & volatility, CTSO or LFWD?

Do insiders and institutionals have more ownership in CTSO or LFWD?

Is CTSO or LFWD more profitable?

Does the media refer more to CTSO or LFWD?

Do analysts recommend CTSO or LFWD?

Which has preferable valuation and earnings, CTSO or LFWD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFWD vs. The Competition

Lifeward Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools